Anticipating the surge of demand for medical cannabis next year, companies in Denmark are queueing to apply for approval to grow the plant.
So far, there have been 13 companies who submitted their applications to grow marijuana. The applications are submitted to the state’s medicines regulating body, Laegemiddelstyrelsen.
Starting January of next year, the country will legalize cannabis as part of a four-year-trial where patients in the country can obtain cannabis prescriptions for various illnesses such as chronic pain caused by cancer and multiple sclerosis.
With only less than three months to deadline, some companies hesitated to apply due to the vagueness in regulatory rules. In fact, the country’s parliament is still working on the details of the scheme.
One horticulturist, Jorgen K. Andersen of the Dansk Gartneri firm said that one of the things that stopped them from forwarding their own application is the potentially complicated set of rules that will govern the cultivation of cannabis.
Yet, other companies have their own agenda. Some are planning to export the drug to regions where marijuana is legal in order to help drive down the cost of acquisition for the country’s domestic patients.
In a month alone, adequate cannabis treatment is projected to cost around 6,000 krone. That’s $935 or £715 correspondingly.
These export-envisioning growers are looking to half the cost and make the treatment more affordable to Denmark’s citizens.
But with time constraints and the current unavailability of clear regulatory directives, the real question is: will they get it?